Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safinamide after DBS in Parkinson's disease
DRKS00037918Phase 4Completed
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of safinamide in Parkinson's disease (PD) (2 arms), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoints: Motor symptoms after DBS with safinamide and Neuropsychiatric symptoms after DBS with safinamide. Started Nov 2025; status: completed.
02
Drugs
safinamide
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on DRKS00037918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00037918.